Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Sonoma Pharmaceuticals Inc SNOA

Sonoma Pharmaceuticals, Inc. is engaged in developing and producing stabilized hypochlorous acid (HOCl), products for a range of applications, including wound care, animal health care, eye care, oral care and dermatological conditions. The Company's product offerings include Regenacyn Advanced Scar Gel, Regenacyn Plus Scar Gel, Rejuvacyn Advanced Skin Repair Cooling Mist, Pediacyn Skin Care... see more

Recent & Breaking News (NDAQ:SNOA)

Sonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United States

Accesswire April 9, 2024

Sonoma Pharmaceuticals Reports Recent Publication from Australia Highlighting Potential for Microdox in Managing Urinary Tract Infections

Accesswire April 4, 2024

Sonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor Conferences

Accesswire March 28, 2024

Sonoma Pharmaceuticals Highlights Safety Advantages of its Microcyn Products in Light of Growing Concerns of Benzene in Many Other Topicals

Accesswire March 27, 2024

Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2024 Financial Results

Accesswire February 8, 2024

Sonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-the-Counter Skincare Product for Daily Use

Accesswire January 23, 2024

Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2024 Financial Results

Accesswire November 13, 2023

Sonoma Pharmaceuticals Announces U.S. Launch of Next Generation Advanced Solution for Pulse Lavage Irrigation at the Symposium on Advanced Wound Care Fall Conference

Accesswire November 3, 2023

Sonoma Pharmaceuticals, Inc. Announces Pricing of $1.7 Million Public Offering of Common Stock

Accesswire October 26, 2023

National Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced

Accesswire August 15, 2023

Sonoma Pharmaceuticals Reports First Fiscal Quarter 2024 Financial Results

Accesswire August 10, 2023

Sonoma Pharmaceuticals Announces Appointment of Hye Jin Chung, M.D. to Scientific Advisory Board

Accesswire August 3, 2023

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2023 Financial Results

Accesswire June 22, 2023

Sonoma Pharmaceuticals Introduces Next Generation Solution for Pulse Lavage Irrigation in the European Union

Accesswire June 8, 2023

Sonoma Pharmaceuticals Introduces Podiacyn, an All Natural, Over-the-Counter Podiatry Product for Daily Foot Care

Accesswire April 11, 2023

Sonoma Pharmaceuticals to Exhibit at Upcoming CPHI North America Conference in Philadelphia

Accesswire March 28, 2023

Sonoma Pharmaceuticals and MicroSafe Group Announce New EPA Claims and Green Seal Certification for Nanocyn(R) Hospital-Grade Disinfectant

Accesswire March 2, 2023

Sonoma Pharmaceuticals Reports Third Quarter 2023 Financial Results

Accesswire February 14, 2023

Sonoma Pharmaceuticals Announces Partnership with Daewoong Pharmaceutical for Distribution of Primocyn Skin Care in South Korea

Accesswire January 31, 2023

Sonoma Pharmaceuticals and EMC Pharma Announce Department of Defense DAPA Registration for Microcyn(R) Rx Products

Accesswire January 25, 2023